Table 1.
Ten reported cases of CDX2-positive thymic adenocarcinoma
| Ref. no. | Age/sex | Histological type | Immunohistochemistry | Serum CEA | |||||
|---|---|---|---|---|---|---|---|---|---|
| CK7 | CK20 | CDX2 | TTF1 | CD5 | CEA | ||||
| 1 | 41/M | NOS | − | + | + | − | − | + | N/A |
| 39/F | Mucinous | + | + | + | − | + | + | N/A | |
| 6 | 59/F | Tubular | Focal + | + | + | − | + | N/A | + |
| 7 | 41/M | Mucinous | Focal + | + | + | − | Focal + | + | N/A |
| 8 | 52/F | Mucinous | − | + | + | − | + | + | − |
| 38/M | Mucinous | + | + | + | − | Focal + | + | + | |
| 55/M | Mucinous | − | + | + | − | Focal + | + | + | |
| 9 | 36/F | Mucinous | + | + | Focal + | − | + | N/A | N/A |
| 10 | 55/M | Papillotubular | + | + | Focal + | − | + | N/A | − |
| 11 | 28/F | Mucinous | Focal + | + | + | − | + | N/A | − |
| Current case | 59/M | NOS | − | + | + | − | + | + | + |
| Ref. no. | Age/sex | Histological type | Primary therapy | Therapy for metastasis or recurrence | |||||
|---|---|---|---|---|---|---|---|---|---|
| Primary surgery | Adjuvant CTx | Adjuvant RT | Outcome | Lesion | Treatment | outcome | |||
| 1 | 41/M | NOS | Yes | None | None | Alive without disease after 18 months | |||
| 39/F | Mucinous | Yes | None | None | 2 recurrences | Mediastinal | Surgery | Alive 159 months after diagnosis | |
| 6 | 59/F | Tubular | Yes | Yes (Palliative chemoradiotherapy and radiotherapy, no detail) | Lung and bone (at diagnosis) | No detail | Alive with aggravated bone and lung metastases after 11 months of follow-up | ||
| 7 | 41/M | Mucinous | Yes | Yes (No detail) | Yes | 2 recurrences | No detail | Surgery | Alive without disease 1 year after 2nd surgery |
| 8 | 52/F | Mucinous | Yes | Yes (CDDP + ETP) | Yes | Recurrence at 7 months | Lung and cervical lymph nodes | CBDCA + PTX | Alive 4 months after recurrence |
| 38/M | Mucinous | Yes | Yes (CBDCA + DTX) | Yes | Recurrence | Bone, malignant pleural and pericardial effusions | No detail | Died 12 months after initial diagnosis | |
| 55/M | Mucinous | Yes | Yes (CBDCA + DTX) | Yes | Recurrence | Lung, sacrum, liver, right adrenal gland and mediastinal lymph nodes | Weekly PTX, CPT-11 | Died 24 months after initial diagnosis | |
| 9 | 36/F | Mucinous | Yes | Yes (CDDP + PTX) | Yes | Recurrence at 1 year | Lung with malignant pleural effusion | No detail | Died 3 months after recurrence |
| 10 | 55/M | Papillotubular | Yes | None | Yes | Alive in 14 months after surgery | |||
| 11 | 28/F | Mucinous | Yes | None | None | 2 recurrences over 2 years’ follow-up | No detail | GEMOX and RT | Alive without disease 6 months after treatment |
| Current case | 59/M | NOS | None | Bone (at diagnosis) | CapeOX, FOLFIRI + cetuximab | Died 6 months after diagnosis | |||
CBDCA carboplatin, CDDP cisplatin, CTx chemotherapy, DTX docetaxel, ETP etoposide, GEMOX gemcitabine and oxaliplatin, N/A not assessed, NOS not otherwise specified, PTX paclitaxel, RT radiotherapy